CFO of MAP PHARMACEUTICALS, INC. (MAPP, Financial) Christopher Y Chai sells 10,000 shares of MAPP on 10/01/2009 at an average price of $10.26 a share.
Located in Mountain View California MAP Pharmaceuticals Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine. Map Pharmaceuticals, Inc. has a market cap of $257 million; its shares were traded at around $10.53 .
MAPP is in the portfolios of George Soros of Soros Fund Management LLC.
Recent Trades of MAP PHARMACEUTICALS, INC. by Directors and Officers:
Located in Mountain View California MAP Pharmaceuticals Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine. Map Pharmaceuticals, Inc. has a market cap of $257 million; its shares were traded at around $10.53 .
MAPP is in the portfolios of George Soros of Soros Fund Management LLC.
Recent Trades of MAP PHARMACEUTICALS, INC. by Directors and Officers:
- Sell: SVP, Cor & Business Dev Anastasios Gianakakos sold 4,500 shares of MAPP stock on 09/08/2009 at the average price of $10.03; the price of the stock has increased by 4.99% since.
- Sell: See footnote 1 Capital, L.l.c. Firstmark sold 9,700 shares of MAPP stock on 07/15/2009 at the average price of $10.56; the price of the stock has decreased by 0.28% since.
- Sell: SVP, Cor & Business Dev Anastasios Gianakakos sold 25,000 shares of MAPP stock on 07/10/2009 at the average price of $10.16; the price of the stock has increased by 3.64% since.
- Sell: See Footnote 1 Capital, L.l.c. Firstmark sold 2,400 shares of MAPP stock on 07/02/2009 at the average price of $12; the price of the stock has decreased by 12.25% since.
- Sell: See Footnote 1 Capital, L.l.c. Firstmark sold 45,000 more shares of MAPP stock on 07/01/2009 at the average price of $12.09; the price of the stock has decreased by 12.9% since.
